

Ausbildung

10/2004 - 05/2011 Medizinstudium an der medizinischen Universität Ulm,
Regionalspital Surselva, Switzerland und Texas Heart Institute, Houston, USA

2011 Approbation

Beruflicher Werdegang

10/2011 – 07/2014 Assistenzärztin für Urologie, Universitätsklinik Ulm, Klinik für
Urologie und Kinderurologie

08/2014 – 09/2018 Assistenzärztin für Urologie, Universitätsklinik Münster, Klinik für
Urologie und Kinderurologie

06/2017 Zusatzbezeichnung "Medikamentöse Tumortherapie"

Seit 10/2018 Oberärztin und Leiterin der medikamentösen Uroonkologie,
Universitätsklinikum Augsburg, Klinik für Urologie

Habilitation

11/2017 Thema: "Prädiktive und prognostische Bedeutung molekularer Biomarker
bei urologischen Tumorerkrankungen"
Westfälische Wilhelms-Universität Münster

Dissertation

05/2011 Thema: "Der Einfluss des small conductance potassium channel
3 (SK3) auf die Zellmorphologie neuraler Stammzellen und primärer hippocampaler
Neurone" Institut für Anatomie und Zellbiologie Universität Ulm
Dissertationbetreuer : Prof. Dr. med. Tobias M. Böcker

Drittmittel

Anneliese-Pohl-Foundation (Detection of Androgenrezeptor
Modifications in Circulating Tumour Cells, 150.000,- Euro), 2014

Preise

04/2016 Paul-Mellin-Award NRWGU

03/2017 EAU Best Paper on Clinical Research Award 2017

Studienerfahrung

Nierenzellkarzinom:

Checkmate214: Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

KEYNOTE-426: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) CaboCare: Prospective Non-interventional Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

Prostatakarzinom:

ERA-223: A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

VIABLE: A Randomized, Double Blind, Multicenter, Parallelgroup, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

PRESIDE: A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone

SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

ARAMIS: A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

ARASENS: A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer

ADAM: A Randomized, Open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Urothelkarzinom:

DANUBE: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

KEYNOTE-045: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer

KEYNOTE-361: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma

AVENUE: A multi-centre noninterventional study to describe the early clinical experience of Avelumab used as monotherapy for the first line maintenance

treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.

Mitgliedschaften

European Society for Medical Oncology (ESMO)

Deutsche Gesellschaft für Urologie (DGU)

European Association of Urology (EAU)

German Society for Residents in Urology (GeSRU)